Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Emerging subcutaneous infusions for PD: efficacy & infusion site reactions

Stuart Isaacson, MD, Director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, presents two studies that shed light on the emerging intermediate class of therapies for Parkinson’s disease. The first study focused on the subcutaneous infusion of apomorphine and discussed its early onset of efficacy, tolerability, and low discontinuation rate in US patients. The second study examined infusion site reactions related to subcutaneous infusion of levodopa-carbidopa, highlighting that these reactions are typically mild or moderate and rarely result in discontinuations. Additionally, findings have shown that subcutaneous infusions are well tolerated by the skin, and infections are not commonly seen. Healthcare professionals are encouraged to monitor and, if necessary, culture any red or inflamed areas, considering possible infection. The overall findings demonstrate the promising potential of these intermediate therapies in improving patient outcomes. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.